Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Nat Med. 2011 Jan 16;17(2):211–215. doi: 10.1038/nm.2284

Figure 1. Underexpression and tumor-inhibitory effects of miR-34a.

Figure 1

a. Experimental scheme. b,c. Lower miR-34a levels in CD44+ xenograft (b; PC4, LAPC4) or primary tumor (HPCa; c) cells. Results are expressed as the mean % of marker-positive over marker-negative cells. d,e. miR-34a inhibited LAPC9 (d) and HPCa58 (e; black, lenti-ctl; grey, lenti-34a; n = 10 and n = 7 for 1° and 2° experiments) tumor growth (mean ± S.D). f. CD44+ Du145 cells infected with lenti-ctl or lenti-34a were injected (10,000 cells each) s.c in NOD-SCID mice. Tumor incidence was 10/10 and mean weight was 0.6 g for lenti-ctl group whereas the incidence for lenti-34a group was 0/10. g. Purified CD44+ LAPC9 cells were transfected with miR-NC or miR-34a and s.c injected. Tumor incidence was 7/8 and mean weight was 0.5 g for miR-NC group whereas incidence was 1/8 and tumor weight was 0.03 g for miR-34a group (P = 0.016, incidence). h. Purified CD44− Du145 cells were transfected with anti-NC or anti-34a and s.c injected. Tumor incidence was 5/8 and mean weight was 0.05 g for anti-NC group whereas incidence was 6/8 and tumor weight was 0.2 g for anti-34a group (P = 0.038, weight). i. Bulk LAPC9 cells were transfected with anti-NC or anti-34a oligos and implanted (100,000 cells) in the DP. Mice were terminated at d 46. Tumor incidences were 5/8 and 7/8 for anti-NC and anti-34a groups, respectively. j. Representative microphotographs (animal number and tumor weight indicated on top; scale bar, 100 μm) showing increased lung metastasis by anti-34a (also see Supplementary Fig. 7c–d).